Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman Unit的抗癌藥物將與上海Allist的Furmonertinib聯合進行臨床試驗
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊